Aclaris Therapeutics (ACRS) Change in Accured Expenses (2017 - 2025)
Historic Change in Accured Expenses for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $1.3 million.
- Aclaris Therapeutics' Change in Accured Expenses rose 21300.17% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 12252.84%. This contributed to the annual value of -$3.9 million for FY2024, which is 13287.47% down from last year.
- Aclaris Therapeutics' Change in Accured Expenses amounted to $1.3 million in Q3 2025, which was up 21300.17% from $399000.0 recorded in Q2 2025.
- Over the past 5 years, Aclaris Therapeutics' Change in Accured Expenses peaked at $11.6 million during Q4 2024, and registered a low of -$12.9 million during Q1 2024.
- In the last 5 years, Aclaris Therapeutics' Change in Accured Expenses had a median value of $399000.0 in 2025 and averaged -$12473.7.
- Per our database at Business Quant, Aclaris Therapeutics' Change in Accured Expenses skyrocketed by 92848.75% in 2023 and then plummeted by 101267.24% in 2024.
- Over the past 5 years, Aclaris Therapeutics' Change in Accured Expenses (Quarter) stood at $2.5 million in 2021, then tumbled by 126.81% to -$681000.0 in 2022, then skyrocketed by 928.49% to $5.6 million in 2023, then surged by 105.1% to $11.6 million in 2024, then tumbled by 88.81% to $1.3 million in 2025.
- Its Change in Accured Expenses was $1.3 million in Q3 2025, compared to $399000.0 in Q2 2025 and -$11.0 million in Q1 2025.